Ocular Therapeutix Inc (OCUL)
6.17
+0.30
(+5.11%)
USD |
NASDAQ |
May 03, 16:00
6.16
-0.01
(-0.16%)
After-Hours: 20:00
Ocular Therapeutix Revenue (TTM): 58.44M for Dec. 31, 2023
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
December 31, 2023 | 58.44M |
September 30, 2023 | 57.72M |
June 30, 2023 | 54.60M |
March 31, 2023 | 51.68M |
December 31, 2022 | 51.49M |
September 30, 2022 | 49.73M |
June 30, 2022 | 49.91M |
March 31, 2022 | 49.37M |
December 31, 2021 | 43.52M |
September 30, 2021 | 38.56M |
June 30, 2021 | 32.28M |
March 31, 2021 | 22.14M |
December 31, 2020 | 17.40M |
September 30, 2020 | 12.31M |
June 30, 2020 | 7.263M |
March 31, 2020 | 6.344M |
December 31, 2019 | 4.227M |
September 30, 2019 | 2.475M |
June 30, 2019 | 2.144M |
Date | Value |
---|---|
March 31, 2019 | 2.142M |
December 31, 2018 | 1.99M |
September 30, 2018 | 1.973M |
June 30, 2018 | 1.998M |
March 31, 2018 | 1.788M |
December 31, 2017 | 1.923M |
September 30, 2017 | 1.947M |
June 30, 2017 | 1.901M |
March 31, 2017 | 1.904M |
December 31, 2016 | 1.887M |
September 30, 2016 | 1.812M |
June 30, 2016 | 1.764M |
March 31, 2016 | 1.782M |
December 31, 2015 | 1.75M |
September 30, 2015 | 1.819M |
June 30, 2015 | 1.533M |
March 31, 2015 | 1.171M |
December 31, 2014 | 0.772M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
2.144M
Minimum
Jun 2019
58.44M
Maximum
Dec 2023
32.19M
Average
38.56M
Median
Sep 2021
Revenue (TTM) Benchmarks
Amgen Inc | 29.53B |
Assertio Holdings Inc | 152.07M |
CytomX Therapeutics Inc | 101.21M |
EyePoint Pharmaceuticals Inc | 46.02M |
Regeneron Pharmaceuticals Inc | 13.10B |